Moleculin's Miracle R/R AML trial reports positive interim data with 37% blinded CRC in venetoclax-failed patients
MBRX•Interim trial data reported
July 31 (Reuters) - Moleculin Biotech Inc. MBRX.O:
- Moleculin’s MIRACLE R/R AML trial reports positive interim data with 37% blinded CRC in venetoclax-failed patients.
- Moleculin Biotech said no evidence of cardiotoxicity was observed with Annamycin in the MIRACLE trial.
- Moleculin Biotech said MIRACLE trial Part A final treatment is expected September 2026; unblinded results are expected December 2026–February 2027.
